TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03193749
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for tablets of 200 mg of Amiodarone
Study: NCT03122613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of Curcumin Placebo per day
Study: NCT00789971
Drug: Maxitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
Study: NCT03916601
Drug: SAR341402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT00616603
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml of normal saline given once intravenously.
Study: NCT03916601
Drug: SAR341402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: suspension for injection~Route of administration: subcutaneous
Study: NCT01893827
Drug: XR-NTX (Extended-Release Naltrexone)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
Study: NCT02425722
Drug: ASP0456
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02425722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03570554
Drug: Naproxen Sodium (Aleve, BAY117031)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
Study: NCT03570554
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
Study: NCT03570554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-encapsulation capsule, 4 days, oral (Treatment D)
Study: NCT00328159
Drug: Oil special 107 and MYGLIOL 810
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03563170
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03563170
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anhydrous
Study: NCT03563170
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin calcium salt
Study: NCT01642485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different meals effect on Moxifloxacin PK profile
Study: NCT02697136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection, USP
Study: NCT02245620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
Study: NCT01316770
Drug: Placebo Parotid Irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
Study: NCT01920048
Drug: Drug Therapy for Heart Failure
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
Study: NCT00035256
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00455520
Drug: CG5503
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100, 150, 200, 250 mg twice daily given for up to 15 weeks
Study: NCT00455520
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo twice daily for 12 weeks
Study: NCT01733043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00889473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule
Study: NCT02232152
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03197870
Drug: AKB-9778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous AKB-9778 15mg
Study: NCT03197870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Placebo
Study: NCT04210375
Drug: JK07
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
Study: NCT04210375
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control
Study: NCT00623649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation study with a full review of all safety data following each cohort.
Study: NCT01477294
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
Study: NCT01477294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malt dextrin (5 mg/kg body mass) twice a day during 4 days
Study: NCT03037736
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be used as the placebo.
Study: NCT01122940
Drug: Epamin: Reference Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 75 mg (10 ml in suspension) of Epamin
Study: NCT01122940
Drug: Phenytoin: Study Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 75 mg (10 ml in suspension) of Phenytoin
Study: NCT02143830
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
Study: NCT00110916
Drug: Intra-articular metHuIL-1ra (anakinra)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anakinra
Study: NCT00110916
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03488225
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03488225
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03488225
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03488225
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV or PO
Study: NCT03448939
Drug: S5G4T-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream
Study: NCT00061022
Drug: NXY-059
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02213094
Drug: Nicotinamide 500 mg
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide 500 mg taken by mouth each morning
Study: NCT02213094
Drug: Nicotinamide 1000 mg
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide 1000 mg taken by mouth each morning
Study: NCT01701089
Drug: RO4602522
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of RO4602522 for 14 days
Study: NCT02861417
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00374218
Drug: Sucromalt
Normalized name: SucroMate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02970019
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day administration after fast
Study: NCT02652455
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
Study: NCT02970019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day administration after fast
Study: NCT01674348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01733459
Drug: DLBS3233
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 DLBS3233 capsule 100 mg once daily for 6 months
Study: NCT01733459
Drug: Placebo capsule of DLBS3233
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule of DLBS3233 once daily for 6 months
Study: NCT01678755
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 High Dose
Study: NCT01678755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04603794
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Study: NCT01504984
Drug: SYO-1126
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
Study: NCT03478306
Drug: Melatonin 4 mg Tablet
Normalized name: Melatonin Tablets
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
Study: NCT03855384
Drug: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
Study: NCT03855384
Drug: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
Study: NCT00982527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
Study: NCT00870168
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01684540
Drug: Sinupret forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290002
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
Study: NCT00070642
Drug: CPG 7909 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
Study: NCT00070642
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2
Study: NCT00070642
Drug: CPG 7909 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
Study: NCT00947024
Drug: 10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03684824
Drug: Long luteal phase GnRH agonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
Study: NCT01580839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study: NCT03684824
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
Study: NCT00648466
Drug: Imitrex® Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT06092736
Drug: Compound Danshen Dropping Pills
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
Study: NCT06092736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
Study: NCT02418065
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02418065
Drug: Oral nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006305
Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
Study: NCT01236950
Drug: Delmopinol mouthrinse
Normalized name: delmopinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial mouthrinse with manufacturer's use indication
Study: NCT01569750
Drug: Part 1, Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study: NCT01569750
Drug: Part 1, Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study: NCT01569750
Drug: Part 1, Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study: NCT03214614
Drug: GLPG2451 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
Study: NCT03214614
Drug: Placebo multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral suspension, daily for 14 days
Study: NCT03214614
Drug: GLPG2451/GLPG2222 multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
Study: NCT03214614
Drug: Combined Placebo multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Placebo, oral suspension, daily for 14 days
Study: NCT01569750
Drug: Part 2, Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
Study: NCT01569750
Drug: Part 2, Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
Study: NCT02603822
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
Study: NCT00662558
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg capsules BID for 6 weeks
Study: NCT01551004
Drug: CRS3123
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
Study: NCT01542034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT01075399
Drug: [F 18]HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
Study: NCT00115037
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparer for 16 weeks in phase 2.
Study: NCT02449902
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 10 µg capsule inserted vaginally for 14 days.
Study: NCT02449902
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule inserted vaginally for 14 days.
Study: NCT03654105
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment will consist of Acetylsalicylic acid at 100mg once a day
Study: NCT02612610
Drug: Placebo (for gefapixant)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04115410
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
Study: NCT00783224
Drug: Placebo for MF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
Study: NCT00783224
Drug: Placebo for FP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
Study: NCT01060878
Drug: PYM50028
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP
Study: NCT01060878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo comprising identical vehicle to active doses
Study: NCT04202263
Drug: Minocycline Topical
Normalized name: minocycline topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
Study: NCT04202263
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of minocycline cream 0%
Study: NCT02930746
Drug: BAY987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
Study: NCT01904318
Drug: IDP-73152 mesylate 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-73152 mesylate 80 mg single dose administration
Study: NCT01904318
Drug: IDP-73152 mesylate 160 mg
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-73152 mesylate 160 mg single dose administration
Study: NCT01904318
Drug: IDP-73152 mesylate 320 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-73152 mesylate 320 mg single dose administration
Study: NCT01904318
Drug: IDP-73152 mesylate 640 mg
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-73152 mesylate 640 mg single dose administration
Study: NCT01904318
Drug: IDP-73152 mesylate 1280 mg
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-73152 mesylate 1280 mg single dose administration
Study: NCT01904318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose administration
Study: NCT01707251
Drug: Intravenous Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
Study: NCT00195988
Drug: tacrolimus, steroids, mycophenolate mofetil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02791308
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03458923
Drug: Diclofenac Sodium 0.1 ml containing 500µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
Study: NCT01080729
Drug: Recombinant-follicle stimulating hormone (r-FSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG).
Study: NCT03605940
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day
Study: NCT00179205
Drug: Nepro nutritional supplement
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.